SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as the community speculates on upcoming catalysts related to MASH and obesity treatments. Discussions revolve around the potential impact of recent FDA qualifications related to AI-driven analysis in liver biopsies, with many anticipating positive data readouts. Some traders are also eyeing a potential "golden cross" pattern and anticipating significant upward movement.

SAIHEAT Ltd. engages in the operation of cryptocurrency mining. It operates Bitcoin for its own account and provides full suite of services, purchase of mining machines, hosting service, and mining pool. The company was founded by Risheng Li on February 2, 2021, and is headquartered in Singapore.

SAIHEAT Ltd. - Ordinary Shares - Class A

SAIHEAT Ltd

SAIH is trending due to speculation around its small modular reactor (SMR) technology potentially being used by Amazon, fueling significant after-hours momentum and a breakout. The stock's low float is a key talking point, with many traders anticipating a potential short squeeze and comparing it to other recent parabolic runners. Community members are actively watching for continued volume and breakout levels, discussing its potential as a play in the AI, energy, and data center space.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the return to OG memes and a growing sense of anticipation for upcoming developments. Discussions revolve around community building, with members expressing strong conviction and encouraging others to join before it's "too late." The focus remains on long-term potential and a collective effort to drive the project forward.

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

VOR is trending due to positive sentiment around a recent Phase 3 clinical study, although opinions are split on whether this will be a long-term catalyst or a short-lived pump, as some traders discuss an upcoming share offering and reverse split. Community members are weighing the potential for a short squeeze against concerns of dilution, with some highlighting institutional ownership and potential undervaluation. The stock's volatile price action and high short interest are fueling active discussions.

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

XCUR is trending due to positive Phase 2 trial results for its cancer treatment, spurring excitement among investors. The community highlights the massive market potential and the stock's low float, which could lead to a short squeeze. However, some traders are wary of a potential offering this week, given the company's previous cash concerns.

AlphaTime Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on September 15, 2021 and is headquartered in New York, NY.

AlphaTime Acquisition Corp

ATMC is trending following shareholder approval of its merger with HCYC Group, driving significant after-hours volume and price action. Community discussions highlight the stock's low float and potential for a short squeeze, with some drawing comparisons to other recent high-flying low float plays. Speculation is rampant regarding potential price targets, with many noting the possible impact of the merger on the company's valuation.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

NCLH is trending due to a recent downgrade from Goldman Sachs, sparking debate among investors about the company's prospects and analyst accuracy. Community members are actively discussing whether the stock is overbought and questioning the validity of analyst ratings, especially compared to JPM's outlook. Overall sentiment is mixed as some see a buying opportunity while others express frustration with the stock's performance.

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita ($DVA) is trending amid discussions about its relationship with Akebia Therapeutics ($AKBA) and potential impacts from new kidney disease treatments, with some traders pointing to trade alerts suggesting possible bullish reversals based on oversold conditions. Community members are scrutinizing Akebia's communications and awaiting DaVita's Q3 earnings report, speculating about potential adoption of new technologies and their effect on patient outcomes. Discussions also involve the potential for mergers and acquisitions within the dialysis space.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the Platform and Devices segments. The Platform segment includes digital advertising and related services including the demand-side platform and content distribution services such as subscription and transaction revenue shares, media and entertainment promotional spending, the sale of premium subscriptions, and the sale of branded channel buttons on remote controls. The Devices segment is involved in the sale of streaming players, audio products, smart home products, and accessories that are sold through retailers and distributors, as well as directly to customers through the company’s website. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

ROKU is trending amid speculation regarding potential acquisitions and renewed interest in streaming and ad-tech. Community members are discussing potential price targets, technical indicators suggesting bullish momentum, and the impact of developments with major media players like Netflix and Warner Bros. The stock's potential as a media-tech squeeze play is also a hot topic.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as the stock experiences a steep drop following a recent earnings report and lowered guidance, prompting discussions about its long-term viability and debt management. The community is analyzing the potential for a turnaround, with some viewing the current price as a buying opportunity due to the company's historical presence and oversold conditions, while others express concern over the dividend cut and overall financial health.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Dyne Therapeutics Stock Was Blasting Higher Today

Key PointsIts No. 1 drug candidate did well in a clinical trial...

Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up Following Analyst Upgrade

Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up After Analyst Upgrade...

HC Wainwright Forecasts Strong Price Appreciation for Dyne Therapeutics (NASDAQ:DYN) Stock

HC Wainwright raised their price target on Dyne Therapeutics from $46.00 to $60.00 and gave the company a "buy" rating in a research report on Monday...

Dyne Therapeutics Stock Down 30% in a Year So Why Did One Investor Add Nearly 1 Million Shares?

Key PointsCalifornia-based Palo Alto Investors acquired 997,698 DYN shares in the third quarter...

Franklin Resources Inc. Cuts Stock Holdings in Dyne Therapeutics, Inc. $DYN

Franklin Resources Inc. lessened its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 1.7% during the second quarter, according to its most recent filing with the Securities and...

Ensign Peak Advisors Inc Has $2.53 Million Position in Dyne Therapeutics, Inc. $DYN

Ensign Peak Advisors Inc grew its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 1,220.5% during the second quarter, according to its most recent 13F filing with the Securities and...

Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eighteen research firms that are presently covering the stock...

Dyne Therapeutics (NASDAQ:DYN) Trading 9% Higher - Here's What Happened

Dyne Therapeutics (NASDAQ:DYN) Shares Up 9% - Still a Buy...

Candriam S.C.A. Purchases 60,793 Shares of Dyne Therapeutics, Inc. $DYN

Candriam S.C.A. grew its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 13.1% during the second quarter, according to the company in its most recent filing with the...

Dyne Therapeutics (NASDAQ:DYN) Price Target Cut to $17.00 by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday...

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.78	--	--	N/A
Q3 '25	-$0.84	-$0.76	9.21%	BEAT
Q2 '25	-$0.94	-$0.97	-2.96%	MISSED
Q1 '25	-$0.85	-$1.05	-22.95%	MISSED
Q4 '24	-$0.91	-$0.88	3.38%	BEAT

DYN
Dyne Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest DYN News

DYNDyne Therapeutics Inc